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Bloodborne viruses may have spread in rural China
during the past 25 years, but population-based prevalence
estimates are lacking. We examined the frequency of hep-
atitis C virus (HCV) and HIV type 1 (HIV-1) among resi-
dents of Linxian, a rural community in Henan Province. In
2000, blood was collected from participants (>55 years of
age) who had enrolled in a population-based nutritional
intervention trial in 1985. We randomly selected 500 partic-
ipants for HCV testing and 200 participants for HIV-1 test-
ing. For HCV, 48 (9.6%) of 500 participants were positive by
enzyme immunoassay and recombinant immunoblot assay
(95% confidence interval, 7.0%–12.2%), and prevalence
was lowest in the most geographically isolated participants.
Among the HCV-infected participants, 42 had a specimen
available from 1985, of which 16 (38.1%) were positive for
HCV. For HIV-1, 0/200 participants were positive. We con-
clude that HCV is now a common infection among older
adults in Linxian, China. 
H
epatitis C virus (HCV) infection is becoming a global
public health problem (1). The overall prevalence of
HCV infection is 1% to 2% in most countries that have
been studied (2), but the distribution of HCV varies con-
siderably among populations. HCV is most frequently
transmitted by percutaneous exposure to infectious blood
or blood-derived body fluids, such as through transfusion
of contaminated blood or blood products, nonsterile med-
ical injections, or injection drug use. Very high rates of
HCV infection are found among persons exposed to HCV
through these routes (3). In a nationwide study conducted
in 1992, HCV prevalence was reported to be 3.2% in
China overall and 3.1% in rural China (4). Other smaller
studies have reported HCV prevalence rates of 0% to 3%
in rural populations from various Chinese provinces (5–7). 
HIV type 1 (HIV-1) infection has been reported among
paid blood donors in rural east central China (8–10).
Because both HIV-1 and HCV are bloodborne, these
reports raise the possibility that HCV may be common in
this area. To date, population-based rates of bloodborne
viral infections in this region are lacking. To provide such
estimates, we used specimens collected as part of a popu-
lation-based study in Linxian, Henan Province, a rural
county in central China where farming is the predominant
occupation (Figure). 
In 2000, surviving participants of a population-based
nutritional intervention trial were resurveyed. The study
had been initiated to study the effect of dietary supple-
ments on the risk of esophageal and gastric cancer, which
occur at very high rates in this region. Participants were
healthy adults from 4 Linxiancommunes who were 40–69
years of age when enrolled in 1985. We used specimens
collected in this study to estimate the prevalence of hepa-
titis B virus (HBV), HCV, and HIV-1 among older adults
in Linxian in 2000. 
Methods
Participants and Samples
In 1985, all healthy adults aged 40–69 years from 4
Linxian communes (Yaocun, Rencun, Donggang, and
Hengshui) were invited to participate in the Linxian
Nutritional Intervention Trial (NIT). NIT is a population-
based trial designed to prevent esophageal and gastric can-
cer, the most common cancers in the Linxian region. Of
≈53,000 potentially eligible participants, 16% refused par-
ticipation, 12% were not living in Linxian at the time due
to temporary employment, 4% were excluded for medical
reasons, and 8% did not join the trial for other reasons (11).
The remaining 32,902 members of the Linxian population
participated in the trial. In 1985, 1 year before the start of
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China the intervention, each participant was interviewed, was
givena brief physical examination, and had blood drawn. 
In 2000, all 23,910 surviving participants were invited
to take part in a follow-up survey; 16,488 participants were
then resurveyed and had blood samples collected. Analysis
of the cause of death from 1985 to 2001 indicated that
most deaths were due to esophageal or gastric cancer
(28%), heart disease (21%), or stroke (31%). About 2% of
deaths were due to cirrhosis and another 2% were due to
liver cancer. Higher death rates among men and older par-
ticipants shifted the demographic pattern among survivors
compared to original enrollees. For example, men com-
prised 40% of participants in 2000 and 44% in 1985. No
difference in the distribution of commune of residence was
found between survivors and all enrollees. 
Ten milliliters of blood was collected in vacutainers
that contained sodium heparin; the samples were stored at
room temperature and transferred within 3 hours to a field
station for processing. Aliquots of plasma were stored at
–85°C until they were shipped on dry ice to a biospecimen
repository in Frederick, Maryland. Participants in the 2000
blood collection survey received the results of their blood
samples, including hematocrit and liver function tests. The
study protocol was approved by institutional review
boards at the U.S. National Cancer Institute and the Cancer
Institute of the Chinese Academy of Medical Sciences. 
For HBV and HCV testing, we selected at random 500
NIT participants who were resurveyed in 2000. In addi-
tion, we tested available specimens that had been drawn in
1985 among participants who we found to be positive for
anti-HCV by recombinant immunoblot assay (RIBA) in
2000. We also randomly selected another 200 NIT partici-
pants from participants resurveyed in 2000 for HIV-1 anti-
body testing. Because HIV-1 testing was not within the
scope of the original study, we removed identifying infor-
mation from these 200 samples and tested them anony-
mously. 
Laboratory Assays
We tested the plasma specimens for HCV antibody by
HCV Version 3.0 enzyme immunoassay (EIA) (Ortho
Diagnostics, Raritan, NJ) according to the manufacturer’s
instructions. Samples that were positive by HCV enzyme
immunoassay EIA were confirmed by HCV Version 3.0
RIBA (Ortho Diagnostics). Because the specimens had
been collected in sodium heparin, which inhibits the poly-
merase chain reaction (PCR), we could not confirm the
presence of HCV by PCR-based assays. As an alternative,
we tested specimens for HCV core antigen (Trak-C, Ortho
Diagnostics). HCV core antigen is a marker of chronic
infection and the analytic sensitivity of the Trak C assay
(Ortho Diagnostics) is similar to that of PCR-based assays
for HCV RNA (12). The 500 samples were also tested for
antibody to HBV core antigen (anti-HBc) by an HBc
ELISA(Ortho Diagnostics). Samples that were positive for
anti-HBc were tested for HBVsurface antigen (HBsAg) by
EIA (Bio-Rad, Redmond, WA). A separate group of 200
samples was tested for HIV-1 antibody by EIA (Genetic
Systems rLAV EIA, Bio-Rad). 
Statistical Methods 
Chi-square analysis was used to compare the preva-
lence of viral infections among participants with different
demographic characteristics. The 95% confidence interval
(95% CI) of prevalence was calculated based on normal
approximation to binomial distribution when that approxi-
mation holds. For rare events, the 95% CI was based on the
Poisson approximation to the binomial distribution. All
statistical analyses were done with the Statistical Analysis
System version 8.0 (SAS, Cary, NC).
Results
Demographic characteristics of the 500 participants
tested for HCVare summarized in the Table. In 2000, more
than half of the participants were 55–64 years of age
(54.2%), 34.4% were 65–74 years, and 11.4% were 75–84
years. This age distribution reflects that participants were
aged 40–69 years when enrolled in 1985. Our study
included 200 (40.0%) men and 300 (60.0%) women. One
hundred seventy (34.0%) participants were from Yaocun,
95 (19.0%) from Rencun, 116 (23.2%) from Donggang,
and 119 (23.8%) from Hengshui.
Of the 500 participants studied, 63 (12.6%) were posi-
tive for HCV antibody by EIA. When the specimens from
these 63 participants were tested by HCV RIBA, 48 were
positive, 7 were indeterminate, and 8 were negative.
Therefore, the estimated prevalence of HCV infection
(defined as positive by both HCV EIAand HCV RIBA) in
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Figure. Eastern part of China showing the locations of Linxian and
Henan Provinces. Adapted from www.Expedia.com.this population in 2000 was 9.6% (95% CI 7.0%–12.2%).
We tested all 23 samples that were positive for HCV
RIBA and had sufficient remaining plasma for HCV core
antigen. HCV core antigen was found in 16 (69.6%) of 23
specimens. 
The prevalence of HCV infection did not differ mean-
ingfully by age or sex (Table), but varied significantly
among the four communes. Donggang, the most geograph-
ically isolated commune, had a lower prevalence of HCV
infection (2.6%) than Yaocun (11.8%, p < 0.01), Rencun
(14.7%, p < 0.01), or Hengshui (9.2%, p = 0.03; p = 0.02,
overall chi-square test). No other significant differences in
HCV prevalence were found between the communes.
Among the 48 participants who were positive by HCV
RIBA in 2000, 42 had specimens available from 1985 for
HCV antibody testing. Of these 42, 16 (38.1%) were posi-
tive by both HCV EIA and HCV RIBA, indicating that
most participants who were infected with HCV in 2000
had acquired the virus since 1985. 
Antibodies to HBV core antigen (HBc), an indicator of
past exposure to HBV, were found in 273 (54.6%) of 500
participants. The prevalence of anti-HBc did not vary sig-
nificantly by age, sex, or commune (Table). Participants
who were infected with HCV had a slightly higher preva-
lence of anti-HBc than those who were not (64.6% vs.
53.5%, p =0.14). Participants who were positive for both
anti-HBc and hepatis B surface antigen (HBsAg), a mark-
er for chronic HBV infection, comprised 6.4% of the pop-
ulation. The prevalence of HBsAg differed relatively little
by age, sex, or commune (Table). 
A separate group of 200 participants was randomly
selected for anonymous testing for antibodies to HIV-1.
These participants included 77 men (38.5%) and 123
women (61.5%). Age as of the year 2000 was distributed
as follows: <59 years, 78 (39.0%); 60–69 years, 76
(38.0%); >70 years, 46 (23.0%). Seventy-two participants
(36.0%) were from Yaocun, 29 (14.5%) were from
Rencun, 48 (24.0%) were from Donggang, and 51 (25.5%)
were Hengshui. None tested positive for antibodies to
HIV-1. The 95% CI for HIV-1 prevalence in this popula-
tion was 0%–0.03%. 
Discussion
In this population-based study of 55- to 84-year-old
persons living in a rural area of Henan Province, HCV
prevalence in 2000 was 9.6%. HCV was present in the
Linxian population in 1985, but most of the HCV-infected
participants in this study likely acquired the virus between
1985 and 2000. In contrast to the high rate of HCV infec-
tion, HIV-1, which also is transmitted through infected
blood, was not found in this population. Evidence of
resolved or chronic HBV infection, which is endemic in
China, was found in about 55% of the participants.
The observed prevalence of HCV in Linxian is higher
than in most previous population-based studies from
China. In the nationwide cross-sectional study conducted
in 1992, HCV prevalence was 3.10% in residents of rural
China and 3.96% in the group aged 50 to 59 years, the eld-
est in that study (4). However, because HCV prevalence in
the nationwide study was determined by HCV EIA alone,
estimates from that study are higher than would have been
obtained with confirmation by HCV RIBA. The RIBA-
confirmed HCV prevalence in Linxian was, therefore, con-
siderably higher than the national rate.
Around the world, the prevalence of HCV infection
appears to be low in most populations (13–15), but areas of
high prevalence have been found. Perhaps the most
notable example is Egypt, where >15% of the population
may be infected with HCV (16,17). Transmission of HCV
occurred in Egypt from the 1960s through the 1980s when
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enteral injections, and unsterilized needles were used (17).
Evidence also exists that HCV infection may have been
transmitted in Egypt through other types of medical care
(18). Iatrogenic transmission may have contributed as well
to high rates of HCV infection that have been reported
from Taiwan (19), Japan (20), and Italy (21).
We could not determine how HCV spread in Linxian
because the nutritional trial did not collect information on
potential exposure to contaminated blood. Widespread
HCV infection in a population generally results from iatro-
genic transmission or sharing of recreational drug injection
equipment. HCV spreads rapidly among injection drug
users, but, to our knowledge, reports of injection drug use
in China are limited to younger age groups in border
provinces and large cities (22,23), not older residents of
inland provinces. It seems unlikely, therefore, that our par-
ticipants acquired HCV infection through injection drug
use. Transmission of HCV has been linked to paid blood
and plasma donations in Central Chinese provinces,
including Henan, during the 1980s and 1990s (24,25).
Reuse of needles and equipment without proper steriliza-
tion and reinfusion of pooled red blood cells from multiple
donors reportedly led to outbreaks of HCV (24,25). These
reports, along with evidence from our study that many
HCV-infected participants acquired the virus between
1985 and 2000, suggest that HCV may have been trans-
mitted among the Linxian population through blood or
plasma collection activities. Our finding of the lowest
HCV prevalence (2.6%) in the most isolated commune
seems consistent with this explanation, since geographic
isolation may have limited the opportunity to contract
HCV infection through these means. 
Outbreaks of HIV-1 have been reported among paid
plasma donors in central Chinese provinces, including
Henan (8–10), but we found no evidence of HIV-1 infec-
tion among 200 randomly selected participants. Our analy-
sis yielded an upper 95% CI of 0.03% for the prevalence
of HIV-1 in this population, which indicates that HIV-1
infection is, at worst, extremely rare among older residents
of Linxian. The absence of HIV-1 in the presence of a rel-
atively high prevalence of HCV is not surprising because
the entry of either virus into a community may depend to
some degree on chance. 
HBV infection is endemic in China (26), and most
transmission occurs during the perinatal period when the
risk of chronic infection is much higher than in adulthood.
Among our participants, 54.6% had HBc, and 6.4% had
both anti-HBc and HBsAg (which indicates chronic infec-
tion). Most or all of the participants who were chronically
infected with HBV likely became infected early in life.
More recent bloodborne transmission may have con-
tributed some participants with resolved HBV infection, as
suggested by the trend toward higher anti-HBc prevalence
among participants who were also infected with HCV. 
The accuracy with which our estimates reflect the
prevalence of viral infections among older Linxian resi-
dents in the year 2000 depends on 2 factors: the test char-
acteristics of the assays we used and how well our study
population represents the target population. The third gen-
eration HCV EIA we used has high sensitivity and speci-
ficity. With confirmation of HCV EIA-positive samples by
a highly specific RIBA, we are unlikely to have overesti-
mated the prevalence of HCV antibodies among our par-
ticipants. We have similar confidence in the assays that we
used for HIV-1 and HBV testing. 
For practical reasons, we used specimens that had been
collected as part of a population-based research effort that
began in 1985. The limitations of our approach for deter-
mining the prevalence of viral infections among Linxian
residents in 2000 should be considered. First, the age cri-
terion of the original study prevented us from ascertaining
infection prevalence among persons <55 years of age.
HCV prevalence may be higher or lower among younger
residents of Linxian. Second, the participants may not rep-
resent older adults residing in Linxian in 2000 with regard
to viral prevalence. About 60% of eligible residents
enrolled in the trial in 1985 and about 70% of surviving
enrollees participated in the 2000 follow-up. If surviving
enrollees who were infected with one of the viruses that we
studied were less likely to participate in the 2000 survey
due to poor health, we may have underestimated the true
prevalence of infection. However, usually a long period
elapses from infection with these viruses to disease, and
our results likely provide a reasonable estimate of viral
prevalence among older residents of Linxian. 
In summary, HCV is now common in this rural Chinese
community, at least among its older residents. In contrast,
we found no evidence of HIV-1 infection in the population.
The public health impact of the high prevalence of HCV
infection in Linxian may be substantial. HCV is an impor-
tant cause of end-stage liver disease and hepatocellular
carcinoma, and it can act synergistically with HBV infec-
tion (27), which is endemic in China. Future studies should
examine the prevalence of bloodborne viruses in other
parts of China, how these viruses are transmitted, and the
resulting health effects. Efforts to halt the transmission of
HCV and other bloodborne viruses in rural China should
be a top public health priority.
This project was funded, in part, by National Cancer
Institute, National Institutes of Health contracts NO1-SC-91030
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